Linco Research
Linco Research is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Linco Research.
Linco Research is a company.
Key people at Linco Research.
Key people at Linco Research.
LINCO Research is a life sciences company that manufactures and markets proprietary immunoassay kits for the drug discovery and development industry.[1][2][4] Based in St. Charles, Missouri (with earlier references to St. Louis), it specializes in reagents and kits for detection in medical testing, clinical laboratories, and healthcare applications, including quantitative assays like human C-peptide radioimmunoassays for serum, plasma, and tissue culture media.[3][7] The company served pharmaceutical and biotech researchers by providing tools for analyzing human and animal research specimens, with reported revenue around $8.4 million at one point.[3][6]
LINCO consisted of two main entities: LINCO Research Inc. (LRI), focused on manufacturing immunoassay kits, and LINCO Diagnostic Services, Inc. (LDS).[5] It addressed key needs in preclinical and clinical research by offering specialized, proprietary immunoassays developed over more than 20 years.[6]
LINCO Research operated for over 20 years, developing and performing immunoassays for human and animal research specimens, with expertise offered to drug discovery sectors.[6] The company was headquartered in St. Charles (and previously St. Louis), Missouri, establishing itself as a manufacturer of reagents and kits.[2][3][5] A pivotal moment came when Serologicals Corporation agreed to acquire LINCO in a $74.8 million deal, highlighting its value in the life sciences space; the acquisition encompassed both LRI and LDS.[5] Specific founding year and founders are not detailed in available records, but its longevity underscores steady growth in immunoassay technology.[1][4]
LINCO Research rode the wave of advancing drug discovery tools in the 1990s and early 2000s, when immunoassays became essential for biomarker detection in preclinical testing amid rising biotech investments.[1][6] Its timing aligned with growth in biopharma R&D, where precise measurement of peptides and proteins accelerated candidate validation. Market forces like demand for animal model research and outsourcing of assay development favored specialized providers like LINCO.[4][5] The $74.8 million acquisition by Serologicals amplified its influence, integrating its kits into larger platforms and contributing to consolidated life sciences tooling ecosystems.[5]
LINCO Research exemplified niche innovation in immunoassay tech, culminating in a high-value acquisition that validated its role in drug development pipelines.[5] Post-acquisition, its technologies likely evolved within Serologicals (now part of larger entities like MilliporeSigma), influencing modern biomarker assays amid trends like AI-driven discovery and personalized medicine. Future impact may lie in legacy contributions to high-throughput screening, as demand for precise, scalable detection grows with complex biologics and gene therapies—positioning its foundational kits as enduring enablers in an increasingly integrated biopharma landscape.
